Developmental changes in neurotransmitter receptor binding in the human periaqueductal gray.
The periaqueductal gray (PAG) plays a central role in the integration of defense responses to threatening or stressful stimuli. Little is known about the neurochemical development of the human PAG around the time of birth, when the fetus makes the transition to extrauterine life and independent defense responses are needed. We analyzed receptor binding to selected neurotransmitters implicated in PAG function in 7 fetuses (19 to 26 gestational weeks), 9 infants (38 to 74 postconceptional weeks), 1 child (4 years), and 3 adults (20 to 68 years). Tissue autoradiography was used with radioligands for opioid, nicotinic, muscarinic, kainate, and serotoninergic receptors. By midgestation, binding to nicotinic, muscarinic, serotoninergic, opioid, and kainate receptors is already localized to the human PAG. The subsequent developmental profiles are unique for each radioligand. Binding to nicotinic and serotoninergic receptors decreases significantly from the fetal to mature periods, but at different tempos. In contrast, there is no significant change from midgestation to infancy for muscarinic, kainate, and opioid binding: between infancy and the mature period there is a downward trend in binding for muscarinic and kainate receptors and an upward trend for opioid receptors. This study provides baseline information about the neurochemical development of the human PAG in early life. This information is of value in considering the neurochemical substrate of the maturation of defense responses in human infancy, and in evaluating potential neurochemical disorders of the developing human PAG.
Reddy
S C
SC
Department of Neurology, Children's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA.
Panigrahy
A
A
White
W F
WF
Kinney
H C
HC
D000367:Age Factors; D001667:Binding, Competitive; D001921:Brain / Q000254:growth & development*; D006801:Humans; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D009270:Naloxone / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000378:metabolism*; D009538:Nicotine / Q000494:pharmacology; D010487:Periaqueductal Gray / Q000378:metabolism*; D018092:Kainic Acid Receptors / Q000187:drug effects
D008238:Lysergic Acid Diethylamide; D009270:Naloxone; D018377:Neurotransmitter Agents; D009538:Nicotine; D018092:Kainic Acid Receptors